Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Acquisitions (2021 - 2022)

Dexcom (DXCM) has disclosed Acquisitions for 2 consecutive years, with $700000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Acquisitions fell 97.78% to $700000.0 in Q3 2022 year-over-year; TTM through Jun 2023 was $700000.0, a 97.9% decrease, with the full-year FY2022 number at $3.9 million, down 87.09% from a year prior.
  • Acquisitions was $700000.0 for Q3 2022 at Dexcom, down from $3.2 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $31.6 million in Q3 2021 to a low of -$1.4 million in Q4 2021.